NIR-responsive carbon-based nanocarriers for switchable on/off drug release and synergistic cancer therapy

2018 ◽  
Vol 6 (47) ◽  
pp. 7794-7799 ◽  
Author(s):  
Rongrong Nie ◽  
Hongji Liu ◽  
Lin Hu ◽  
Xinyu Gu ◽  
Junchao Qian ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Drug Release ◽  
Drug Delivery System ◽  
Delivery System ◽  
Nir Light ◽  
Carbon Based

This communication reports a chitosan-gated carbon-based nanocarrier as a NIR light-switchable drug delivery system for controlled on/off drug release.

scholarly journals Novel concept of the smart NIR-light–controlled drug release of black phosphorus nanostructure for cancer therapy

2018 ◽  
Vol 115 (3) ◽  
pp. 501-506 ◽  
Author(s):  
Meng Qiu ◽  
Dou Wang ◽  
Weiyuan Liang ◽  
Liping Liu ◽  
Yin Zhang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Drug Release ◽  
Drug Delivery System ◽  
Delivery System ◽  
Near Infrared ◽  
Black Phosphorus ◽  
Deep Penetration ◽  
Nir Light

A biodegradable drug delivery system (DDS) is one the most promising therapeutic strategies for cancer therapy. Here, we propose a unique concept of light activation of black phosphorus (BP) at hydrogel nanostructures for cancer therapy. A photosensitizer converts light into heat that softens and melts drug-loaded hydrogel-based nanostructures. Drug release rates can be accurately controlled by light intensity, exposure duration, BP concentration, and hydrogel composition. Owing to sufficiently deep penetration of near-infrared (NIR) light through tissues, our BP-based system shows high therapeutic efficacy for treatment of s.c. cancers. Importantly, our drug delivery system is completely harmless and degradable in vivo. Together, our work proposes a unique concept for precision cancer therapy by external light excitation to release cancer drugs. If these findings are successfully translated into the clinic, millions of patients with cancer will benefit from our work.

A pH-responsive AIE nanoprobe as a drug delivery system for bioimaging and cancer therapy

2015 ◽  
Vol 3 (37) ◽  
pp. 7401-7407 ◽  
Author(s):  
Haibo Wang ◽  
Gongyan Liu ◽  
Shihua Dong ◽  
Junjie Xiong ◽  
Zongliang Du ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Drug Release ◽  
Drug Delivery System ◽  
Delivery System ◽  
Cellular Imaging ◽  
Ph Responsive ◽  
Triggered Drug Release

A multifunctional drug delivery system with AIE character was designed and constructed for simultaneous cellular imaging and pH-triggered drug release.

scholarly journals An aptamer-targeting photoresponsive drug delivery system using “off–on” graphene oxide wrapped mesoporous silica nanoparticles

Nanoscale ◽  
2015 ◽  
Vol 7 (14) ◽  
pp. 6304-6310 ◽  
Author(s):  
Yuxia Tang ◽  
Hao Hu ◽  
Molly Gu Zhang ◽  
Jibin Song ◽  
Liming Nie ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Graphene Oxide ◽  
Cancer Therapy ◽  
Drug Release ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Drug Delivery System ◽  
Delivery System ◽  
Mesoporous Silica Nanoparticles ◽  
Targeted Cancer Therapy

A photoresponsive drug delivery system was developed for light-mediated drug release and aptamer-targeted cancer therapy.

scholarly journals pH and Redox Dual-Responsive MSN-S-S-CS as a Drug Delivery System in Cancer Therapy

Materials ◽  
2020 ◽  
Vol 13 (6) ◽  
pp. 1279 ◽  
Author(s):  
Yanqin Xu ◽  
Liyue Xiao ◽  
Yating Chang ◽  
Yuan Cao ◽  
Changguo Chen ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Drug Release ◽  
Drug Delivery System ◽  
Delivery System ◽  
Release Rate ◽  
Drug Loading ◽  
Impregnation Method ◽  
Amino Groups ◽  
Dual Responsive

In order to achieve a controlled release drug delivery system (DDS) for cancer therapy, a pH and redox dual-responsive mesoporous silica nanoparticles (MSN)-sulfur (S)-S- chitosan (CS) DDS was prepared via an amide reaction of dithiodipropionic acid with amino groups on the surface of MSN and amino groups on the surface of CS. Using salicylic acid (SA) as a model drug, SA@MSN-S-S-CS was prepared by an impregnation method. Subsequently, the stability, swelling properties and drug release properties of the DDS were studied by x-ray diffraction, scanning electron microscopy, Fourier transform infrared microspectroscopy, size and zeta potential as well as Brunauer–Emmett–Teller surface area. Pore size and volume of the composites decreased after drug loading but maintained a stable structure. The calculated drug loading rate and encapsulation efficiency were 8.17% and 55.64%, respectively. The in vitro drug release rate was 21.54% in response to glutathione, and the release rate showed a marked increase as the pH decreased. Overall, double response functions of MSN-S-S-CS had unique advantages in controlled drug delivery, and may be a new clinical application of DDS in cancer therapy.

Development and Evaluation of Floating Pulsatile Drug Delivery System Using Meloxicam

2017 ◽  
Vol 7 (04) ◽  
Author(s):  
ShirishaG. Suddala ◽  
S. K. Sahoo ◽  
M. R. Yamsani
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Delivery ◽  
Drug Release ◽  
Drug Delivery System ◽  
Delivery System ◽  
Lag Time ◽  
Oral Dosage ◽  
Lag Phase ◽  
Pulsatile Drug Delivery

Objective: The objective of this research work was to develop and evaluate the floating– pulsatile drug delivery system (FPDDS) of meloxicam intended for Chrono pharmacotherapy of rheumatoid arthritis. Methods: The system consisting of drug containing core, coated with hydrophilic erodible polymer, which is responsible for a lag phase for pulsatile release, top cover buoyant layer was prepared with HPMC K4M and sodium bicarbonate, provides buoyancy to increase retention of the oral dosage form in the stomach. Meloxicam is a COX-2 inhibitor used to treat joint diseases such as osteoarthritis and rheumatoid arthritis. For rheumatoid arthritis Chrono pharmacotherapy has been recommended to ensure that the highest blood levels of the drug coincide with peak pain and stiffness. Result and discussion: The prepared tablets were characterized and found to exhibit satisfactory physico-chemical characteristics. Hence, the main objective of present work is to formulate FPDDS of meloxicam in order to achieve drug release after pre-determined lag phase. Developed formulations were evaluated for in vitro drug release studies, water uptake and erosion studies, floating behaviour and in vivo radiology studies. Results showed that a certain lag time before drug release which was due to the erosion of the hydrophilic erodible polymer. The lag time clearly depends on the type and amount of hydrophilic polymer which was applied on the inner cores. Floating time and floating lag time was controlled by quantity and composition of buoyant layer. In vivo radiology studies point out the capability of the system of longer residence time of the tablets in the gastric region and releasing the drug after a programmed lag time. Conclusion: The optimized formulation of the developed system provided a lag phase while showing the gastroretension followed by pulsatile drug release that would be beneficial for chronotherapy of rheumatoid arthritis and osteoarthritis.

Sign in / Sign up

Export Citation Format

Share Document